NNVC Profile
NanoViricides, Inc., a pioneering nano-biopharmaceutical research and development firm based in Shelton, Connecticut, specializes in the discovery, development, and commercialization of innovative antiviral therapies. Founded in 2005, the company focuses on leveraging advanced nanotechnology to create novel treatments for a range of viral infections. Its approach involves designing and developing drugs that specifically target and neutralize viruses using nanoviricides, a class of antiviral agents with high specificity and efficacy.
The company’s key projects include the development of Monkeypox Treatment, a targeted therapeutic solution for combating the Monkeypox virus. NanoViricides is also advancing its Adenovirus 71 Treatment, aimed at addressing severe pediatric hepatitis caused by Adenovirus 71 and related strains. In addition, the HerpeCide Program Expansion focuses on broad-spectrum nanoviricide drugs that address various herpes viruses, catering to multiple indications and demonstrating the company’s commitment to tackling complex viral infections.
NanoViricides’ pipeline includes FluCide, a versatile anti-influenza nanoviricide available in both injectable forms for hospitalized patients and oral forms for outpatient use. The company is also developing Nanoviricide eye drops designed for the treatment of viral infections affecting the external eye, along with DengueCide, a targeted therapy for multiple types of Dengue viruses. HIVCide, another significant project, aims to provide an escape-resistant nanoviricide for effective HIV treatment.
Beyond these projects, NanoViricides is actively exploring additional nanoviricides drug candidates for various viral infections, reflecting its ongoing dedication to expanding its therapeutic offerings. The company's innovative approach and commitment to advancing nanomedicine position it at the forefront of antiviral drug development, with a focus on delivering targeted and effective solutions for challenging viral diseases.
|
